Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

253 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061.
Rudek MA, Moore PC, Mitsuyasu RT, Dezube BJ, Aboulafia D, Gerecitano J, Sullivan R, Cianfrocca ME, Henry DH, Ratner L, Haigentz M Jr, Dowlati A, Little RF, Ivy SP, Deeken JF. Rudek MA, et al. Among authors: dowlati a. Cancer. 2014 Apr 15;120(8):1194-202. doi: 10.1002/cncr.28554. Epub 2014 Jan 28. Cancer. 2014. PMID: 24474568 Free PMC article. Clinical Trial.
A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer.
Dowlati A, Robertson K, Cooney M, Petros WP, Stratford M, Jesberger J, Rafie N, Overmoyer B, Makkar V, Stambler B, Taylor A, Waas J, Lewin JS, McCrae KR, Remick SC. Dowlati A, et al. Cancer Res. 2002 Jun 15;62(12):3408-16. Cancer Res. 2002. PMID: 12067983 Clinical Trial.
A phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU5416 and paclitaxel in recurrent or metastatic carcinoma of the head and neck.
Cooney MM, Tserng KY, Makar V, McPeak RJ, Ingalls ST, Dowlati A, Overmoyer B, McCrae K, Ksenich P, Lavertu P, Ivy P, Hoppel CL, Remick S. Cooney MM, et al. Among authors: dowlati a. Cancer Chemother Pharmacol. 2005 Mar;55(3):295-300. doi: 10.1007/s00280-004-0871-5. Epub 2004 Nov 6. Cancer Chemother Pharmacol. 2005. PMID: 15538570 Clinical Trial.
Inflammatory breast cancer as a model disease to study tumor angiogenesis: results of a phase IB trial of combination SU5416 and doxorubicin.
Overmoyer B, Fu P, Hoppel C, Radivoyevitch T, Shenk R, Persons M, Silverman P, Robertson K, Ziats NP, Wasman JK, Abdul-Karim FW, Jesberger JA, Duerk J, Hartman P, Hanks S, Lewin J, Dowlati A, McCrae K, Ivy P, Remick SC. Overmoyer B, et al. Among authors: dowlati a. Clin Cancer Res. 2007 Oct 1;13(19):5862-8. doi: 10.1158/1078-0432.CCR-07-0688. Clin Cancer Res. 2007. PMID: 17908980 Clinical Trial.
Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine.
Krishnamurthi SS, Brell JM, Hoppel CL, Egorin MJ, Weaver KC, Li X, Ingalls ST, Zuhowski EG, Schluchter MD, Dowlati A, Cooney MM, Gibbons J, Overmoyer BA, Ivy SP, Remick SC. Krishnamurthi SS, et al. Among authors: dowlati a. Cancer Chemother Pharmacol. 2009 Feb;63(3):441-50. doi: 10.1007/s00280-008-0754-2. Epub 2008 Apr 15. Cancer Chemother Pharmacol. 2009. PMID: 18414865 Free PMC article. Clinical Trial.
A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma.
Brell JM, Krishnamurthi SS, Javle M, Saltzman J, Wollner I, Pelley R, Dowlati A, Kantharaj BN, Schluchter MD, Rath L, Ivy SP, Remick SC. Brell JM, et al. Among authors: dowlati a. Cancer Chemother Pharmacol. 2009 Apr;63(5):851-7. doi: 10.1007/s00280-008-0807-6. Epub 2008 Aug 1. Cancer Chemother Pharmacol. 2009. PMID: 18670776 Free PMC article. Clinical Trial.
Phase I trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical cancer.
Kunos CA, Waggoner S, von Gruenigen V, Eldermire E, Pink J, Dowlati A, Kinsella TJ. Kunos CA, et al. Among authors: dowlati a. Clin Cancer Res. 2010 Feb 15;16(4):1298-306. doi: 10.1158/1078-0432.CCR-09-2469. Epub 2010 Feb 9. Clin Cancer Res. 2010. PMID: 20145183 Free PMC article. Clinical Trial.
Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432.
LoRusso PM, Venkatakrishnan K, Ramanathan RK, Sarantopoulos J, Mulkerin D, Shibata SI, Hamilton A, Dowlati A, Mani S, Rudek MA, Takimoto CH, Neuwirth R, Esseltine DL, Ivy P. LoRusso PM, et al. Among authors: dowlati a. Clin Cancer Res. 2012 May 15;18(10):2954-63. doi: 10.1158/1078-0432.CCR-11-2873. Epub 2012 Mar 6. Clin Cancer Res. 2012. PMID: 22394984 Free PMC article. Clinical Trial.
Phase I trial of sunitinib and gemcitabine in patients with advanced solid tumors.
Brell JM, Krishnamurthi SS, Rath L, Bokar JA, Savvides P, Gibbons J, Cooney MM, Meropol NJ, Ivy P, Dowlati A. Brell JM, et al. Among authors: dowlati a. Cancer Chemother Pharmacol. 2012 Oct;70(4):547-53. doi: 10.1007/s00280-012-1936-5. Epub 2012 Aug 7. Cancer Chemother Pharmacol. 2012. PMID: 22868341 Free PMC article. Clinical Trial.
253 results